Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Heron Therapeutics, Inc. (NASDAQ: HRTX)
HRTX Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
7.80%
Analyst Rating:
BUY
Analyst Forecast (1yr):
123.80%
HRTX Stock Analysis
HRTX
PE Ratio:
HRTX
PEG Ratio:
Not Available
HRTX
Forward EPS Growth (12 month):
0.00%
HRTX
PS Ratio:
0.5
HRTX
PSG Ratio:
HRTX
Forward Revenue Growth (12 month):
13.60%
HRTX Articles
No data was found